Therapix is building a specialty pharmaceutical company focused on significantly enhancing FDA-approved dronabinol for the treatment of Tourette Syndrome and Mild Cognitive Impairment.
DR. ELRAN HABER
Chief Executive Officer
Dr. Haber has served as Therapix’s Chief Executive Officer since November 2015. Previously, Dr. Haber had served as the company’s Vice President of Business Strategy and Innovation, beginning in March of 2014. Dr. Haber spent more than 10 years as Chairman and board member of several privately held, and publicly traded, companies including Issta Lines Ltd. (TASE: “ISTA”) from 2007 to 2012, American Express Global Business Travel — Israel (Histour-Eltive Ltd.) from 2010 to 2012, and has been a member of various board committees. Dr. Haber has served in senior executive roles in various life science companies and a private investment firm. Dr. Haber holds a Ph.D. in Pharmaceutical Science and an M.B.A. in Finance & Financial Engineering, both from The Hebrew University of Jerusalem, Israel.
Chief Financial Officer
Mr. Blacher joined Therapix in 2017 bringing with him more than nine years of experience in biotech-related financial management, including as a CFO of a NASDAQ-traded company, business development, investing and operations, as well as 14 years in capital markets. Prior to joining Therapix, Mr. Blacher was the CFO for Galmed Pharmaceuticals, and earlier served as Director of Business Development at Teva Innovative Ventures, Teva Pharmaceuticals’ early- and mid-stage investment and in-licensing arm. In that capacity, Mr. Blacher helped build and manage Teva’s portfolio of approximately 20 equity investments in biotech entities, spanning a wide range of development stage companies from pre-clinical through Phase III projects, and various therapeutic areas. Mr. Blacher also held positions in portfolio management at Deutsche Asset Management and equity research at Morgan Stanley, as well as in mergers & acquisitions at Lehman Brothers. Mr. Blacher holds an MBA in Finance from Columbia Business School.
DR. ADI ZULOFF-SHANI
Chief Technology Officer
Dr. Adi Zuloff-Shani has served as Chief Technologies Officer at Therapix since February 2016, bringing with her more than 15 years of experience as an R&D executive. From 2012 until 2016, Dr. Zuloff–Shani served as a Vice President of Development at Macrocure Ltd. (NASDAQ: “MCUR”) where, aside from leading all research and development activities, she interacted, and was involved, with the activities of all departments including clinical, operations, quality assurance, quality control, finance, and regulatory affairs. Prior to that, Dr. Zuloff-Shani spent eight years as the Senior Scientist in the Research & Development Unit of Magen David Adom’s National Blood Services. Dr. Zuloff-Shani holds a Ph.D. in human biology and immunology from Bar-Ilan University, Israel.
DORON BEN AMI
Chief Strategy Officer
Mr. Doron Ben Ami has been Therapix’s Chief Strategy Officer since December 2015. A seasoned executive with more than 20 years of management experience, he has held various leadership roles in the multinational pharmaceutical industry. Mr. Ben Ami previously held a range of executive positions including Associate Vice President for the Eastern European and Israel region at Merck (from 2010 to 2015), Managing Director of the Merck subsidiary in Israel (from 2008 to 2010), and General Manager of Lundbeck Israel (from 2002 to 2008). Since 2015, Mr. Ben Ami has served as a Senior Consultant at The Harel Group Inc., a U.S. based business development advisory firm that connects innovative pharmaceutical companies with strategic partners. Mr. Ben Ami holds a Master of Health Systems Administration degree (M.H.A.) from Tel Aviv University, Israel.